Gene editing biotech Verve indicates a swift swerve onto Wall Street, asking for $100M IPO

Verve Therapeutics, on the march toward the clinic with a next-gen heart drug, wants a piece of the ever-growing biotech IPO pie.

Verve debuted just over two years ago with $58.5 million and a goal to bring one-and-done gene editing treatments to heart disease.